Alan Skarbnik, Director of the Lymphoma & CLL Program and Immune Effector Cell Therapeutics Program at Novant Health, shared a post on X:
“In the US we argue CAR-T vs bispecifics while 36% of Latin America fights for access to rituximab.
Let that sink in.
GELL Survey 2025 – 73 centers, 16 countries:
- 73% highly restricted access to bispecifics
- ~0% commercial CAR-T outside Brazil
- Only 15% have NGS
- Only 35% access to clinical trials
We’re having 2026 debates with early 2000s access.
The real question isn’t CAR-T vs bispecifics. It’s: how do we close this gap?
Sobering data presented by Miguel Canales here in Chile.”
Title: Access to diagnostics, therapies, and advanced care for lymphoma in Latin America: A multicenter, survey-based study
Authors: Perla R. Colunga-Pedraza, Héctor Alejandro Vaquera Alfaro, Alia Guadalupe Ordoñez Ayala, Carlos Emir Córdova Lucio, Alejandra De Las Fuentes, Laura Korin, Guilherme Perini, Luis Mario Villela Martinez, David Gomez-Almaguer, Henry Idrobo, Juan Rangel-Patiño, Myrna Candelaria, Denisse Castro, Brady Beltran, Fabiola Valvert, Ana Oliver, Camila Peña, Marialejandra Torres Viera, Alana von Glasenapp, Alfredo Quiroz, Rosa Rios Jimenez, Eliana Miranda, and Luis Malpica
Other articles on Cancer in Latin America on OncoDaily.